1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017.CA Cancer J Clin. 2017; 67: 7-30.
2. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012; 30:195-200.
3.Steele CB, Li J, Huang B, Weir HK.Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017;123 Suppl 24(Suppl 24):5160-5177.
4.Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016;70:862-874.
5.Qi D, Wu C, Liu F, Gu K, Shi Z, Lin X, et al. Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009. Prostate. 2015;75:1662-8.
6.Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-32.
7.Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in china: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019;39: 22.
8.Talab SS, Preston MA, Elmi A, Tabatabaei S. Prostate cancer imaging: what the urologist wants to know. Radiol. Clin North Am. 2012; 50:1015-41.
9.Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer:a multidisciplinary perspective. Radiology. 2007; 243: 28-53.
10.Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging.Acta Radiol. 2008; 49:107-20.
11.Fletcher JW, Djulbegovic B, Soares HP, Siegel,BA, Lowe VJ, Lyman JH, et al. Recommendations on the use of 18F-FDG PET in oncology.J Nucl Med. 2008; 49:480-508. 12.Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med. 2013;54:1685-8. 13.Jadvar H. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.J Nucl Med. 2016; 57: 25S-29S.
14.Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesany N, Dujardin T, et al. Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. Eur Urol Focus. 2019; 5: 998-1006.
15.Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer.J Pathol. 2011; 223: 283-94.
16.Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011; 52: 81-9.
17.Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008; 49: 43S-63S.
18.Kwee SA, Lim J. Meyabolic positron emission tomography imaging of cancer: Pairing lipid metabolism with glycolysis. World J Radiol. 2016; 8: 851-856.
19.Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight.Nat Rev Cancer. 2013; 13: 227-32.
20.Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer.Biochim. Biophys Acta. 2013; 1831: 1518-32.
21.Giunchi F, Fiorentino M, Loda M. The Metabolic Landscape of Prostate Cancer. Eur Urol Oncol. 2019; 2: 28-36.
22.Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000; 16: 202-8.
23.Olsen AM, Eisenberg BL, Kuemmerle NB,Flanagan AJ, Morganelli PM, Lombardo PS, et al. Fatty acid synthase is a therapeutic target in human liposarcoma.Int J Oncol. 2010; 36:1309-14 . 24.Yoshii Y, Furukawa T, Saga T,Fujibayashi Y. Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis: overview and application. Cancer Lett. 2015; 356: 211-216.
25.Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010; 6: 551-62.
26.Walz JZ, Saha J, Arora A, Khammanivong A, O'Sullivan MG, Dickerson EB. Fatty acid synthase as a potential therapeutic target in feline oral squamous cell carcinoma. Vet Comp Oncol. 2018; 16: E99-E108.
27.Bastos DC, Paupert J, Maillard C, Seguin F, Carvalho MA, Agostini M, et al. Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model.Lab Invest. 2017; 97: 194-206.
28.Lin HP, Cheng ZL, He RY, Song L, Tian MX, Zhou LS, et al. Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth. Cancer Res. 2016; 76:6924-6936.
29.You BJ, Hour MJ, Chen LY, Luo SC, Hsu PH, Lee HZ. Fenofibrate induces human hepatoma Hep3B cells apoptosis and necroptosis through inhibition of thioesterase domain of fatty acid synthase. Sci Rep. 2019;9:3306.
30.Grube S, Dünisch P, Freitag D, Klausnitzer M, Sakr Y, Walter J, et al. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis. J Neurooncol. 2014; 118: 277-287.
31.Czumaj A, Zabielska J, Pakiet A, Mika A, Rostkowska O, Makarewicz W, et al. In Vivo Effectiveness of Orlistat in the Suppression of Human Colorectal Cancer Cell Proliferation. Anticancer Res. 2019; 39: 3815-3822.
32.Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Taja-Chayeb L, Morales-Barcenas R, Trejo-Becerril C, et al. Orlistat as a FASN inhibitor and multitargeted agent for agent for cancer therapy. Expert Opin Investig Drugs. 2018; 27: 475-489.
33.Wang Y, Christopher BA, Wilson KA, Muoio D, McGarrah RW, Brunengraber H, et al. Propionate-induced changes in cardiac metabolism, notably CoA trapping, are not altered by l-carnitine. Am J Physiol Endocrinol Metab. 2018; 315: E622-E633.
34.Röhrig F Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016; 16: 732-749.
35.Pillarsetty N, Punzalan B, Larson SM. 2-18F-Fluoropropionpic acid as a PET imaging agent for prostate cancer.J Nucl Med. 2009; 50: 1709-14.
36.Zhang ZW, Liu SY, Tang XL, Nie DH, Tang GH, Sun AX, et al. Radiosynthesis and preliminary biological evaluation of the 2-[18F]fluoropropionic acid enantiomers for tumor PET imaging. J Radi Nucl Chem. 2018; 316: 153-159.
37.o J, Zhang Z, Nie D, Ma H, Yuan GJ, Su S, et al. PET Imaging of Hepatocellular Carcinomas: 18F-Fluoropropionic Acid as a Complementary Radiotracer for 18F-Fluorodeoxyglucose. Mol Imaging. 2019; 18: 1536012118821032.
38.Zhang Z, Liu S, Ma H, Nie DH, Wen FH, Zhao J, et al. Validation of R- 2-[18F]Fluoropropionic Acid as a Potential Tracer for PET imaging of liver Cancer. Mol Imaging Biol. 2019; 21: 1127-1137.
39. Ward PS. Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.Cancer Cell. 2012; 21: 297-308.
40. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth.Nat Cell Biol. 2015; 17: 351-9.
41. Venneti S, Dunphy MP, Zhang H,L. Pitter K, Zanzonico P, Campos C, et al. 18Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med. 2015; 7: 247ra17.
42.Lindhe O, Sun A, Ulin J, Rahman O, Långström B, Sörensen J. [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology. Eur J Nucl Med Mol Imaging. 2009; 36: 1453-9.
43. Spick C, Herrmann K, Czernin J. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. J Nucl Med. 2016; 57: 30S-37S.
44.Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008; 49: 327-34.
45.Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Laforest R, et al.18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med. 2007; 48: 420-8.